Servier's Vorasidenib Receives Approval as Clinical Urgently Needed Drug to be Used in Boao Lecheng Pilot Zone

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Servier-China-approve

More Like This

PR Newswire associated0

Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions

Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

PR Newswire associated0

U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China

PR Newswire associated0

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer